Details of the Drug Combination

General Information of Drug Combination (ID: DCJNDX2)

• Drug Combination Name: LY2874455 + Exherin
• Indication: Ewing sarcoma; Status: Investigative [1]
• Component Drugs:
  LY2874455 (DMZ0DMY): Small molecular drug
  Exherin (DMC1I56): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: TC-71
  Zero Interaction Potency (ZIP) Score: 7.354
  Bliss Independence Score: 6.108
  Loewe Additivity Score: 2.624
  LHighest Single Agent (HSA) Score: 4.645

Molecular Interaction Atlas of This Drug Combination

Indication(s) of LY2874455

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

LY2874455 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Fibroblast growth factor receptor 2 (FGFR2)	TTGJVQM	FGFR2_HUMAN	Modulator	[4]

Indication(s) of Exherin

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

Exherin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Neural cadherin (CDH2)	TT1WS0T	CADH2_HUMAN	Binder	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8104).
• [3] ClinicalTrials.gov (NCT00264433) A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent. U.S. National Institutes of Health.
• [4] Company report (Eli Lilly) (drug: LY2874455)
• [5] Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5.